Cas no 74852-61-2 (1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine)
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Chemical and Physical Properties
Names and Identifiers
-
- 1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine
- 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine
- 1-(4-methoxyphenyl)-4-(4-nitrophenyl)-piperazine
- 1-(4-methoxyphonyl)-4-(4-nitrophenyl)piperazine
- N-(4-methoxyphenyl)-N'-(4-nitrophenyl)-piperazine
- PIP024
- SR-01000525959
- 1-{4-nitrophenyl}-4-(4-methoxyphenyl)piperazine
- AG-205/13056226
- 1-(4-Methoxy-phenyl)-4-(4-nitro-phenyl)-piperazine
- Z31269021
- MFCD01604435
- FT-0641542
- Oprea1_198905
- SR-01000525959-1
- AC-10977
- DTXSID50408653
- C2AR3479AC
- 1-(4-METHOXYPHENYL)-4-(4-NITROPHENYL) PIPERAZINE
- BS-49350
- Piperazine, 1-(4-methoxyphenyl)-4-(4-nitrophenyl)-
- AVCKOFMRPAJEPN-UHFFFAOYSA-N
- AKOS001131144
- AMY40877
- 74852-61-2
- SCHEMBL2550023
- CS-0130126
- A838239
- DTXCID00359505
- STK761016
- DB-049834
- 1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine; Posaconazole Impurity
-
- MDL： MFCD01604435
- Inchi： 1S/C17H19N3O3/c1-23-17-8-6-15(7-9-17)19-12-10-18(11-13-19)14-2-4-16(5-3-14)20(21)22/h2-9H,10-13H2,1H3
- InChI Key： AVCKOFMRPAJEPN-UHFFFAOYSA-N
- SMILES： O(C)C1C=CC(=CC=1)N1CCN(C2C=CC(=CC=2)[N+](=O)[O-])CC1
Computed Properties
- Exact Mass: 313.14300
- Monoisotopic Mass: 313.14264148g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 23
- Rotatable Bond Count: 4
- Complexity: 377
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.4
- Topological Polar Surface Area: 61.5?2
Experimental Properties
- Color/Form: Brown solid
- Density: 1.239
- Boiling Point: 515.7?°C at 760 mmHg
- Flash Point: 265.7oC
- Refractive Index: 1.61
- PSA: 61.53000
- LogP: 3.58320
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Security Information
- Storage Condition：Sealed in dry,2-8°C(BD16701)
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Customs Data
- HS CODE：2933599090
- Customs Data：
China Customs Code:
2933599090Overview:
2933599090. Other compounds with pyrimidine ring in structure(Including other compounds with piperazine ring on the structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chemenu | CM169500-5g |
1-(4-methoxyphenyl)-4-(4-nitrophenyl)piperazine |
74852-61-2 | 95+% | 5g |
$640 | 2021-08-05 | |
| Alichem | A139002046-1g |
1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine |
74852-61-2 | 97% | 1g |
$400.00 | 2023-09-01 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-YL574-50mg |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine |
74852-61-2 | 97% | 50mg |
219.0CNY | 2021-07-14 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-YL574-200mg |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine |
74852-61-2 | 97% | 200mg |
549.0CNY | 2021-07-14 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD16701-100mg |
1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine |
74852-61-2 | 97% | 100mg |
￥262.0 | 2024-04-18 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD16701-250mg |
1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine |
74852-61-2 | 97% | 250mg |
￥436.0 | 2024-04-18 | |
| SHANG HAI BI DE YI YAO KE JI GU FEN Co., Ltd. | BD16701-1g |
1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine |
74852-61-2 | 97% | 1g |
￥1174.0 | 2024-04-18 | |
| TRC | M266190-100mg |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine |
74852-61-2 | 100mg |
$ 98.00 | 2023-09-07 | ||
| TRC | M266190-250mg |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine |
74852-61-2 | 250mg |
$ 184.00 | 2023-04-15 | ||
| TRC | M266190-500mg |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine |
74852-61-2 | 500mg |
$ 339.00 | 2023-04-15 |
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Suppliers
Audited Supplier
Audited Supplier
1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine Related Literature
-
Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
-
Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
Additional information on 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine
Recent Advances in the Study of 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine (CAS: 74852-61-2)
The compound 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine (CAS: 74852-61-2) has garnered significant attention in recent years due to its potential applications in the field of chemical biology and medicinal chemistry. This piperazine derivative has been the subject of numerous studies aimed at elucidating its pharmacological properties, mechanism of action, and therapeutic potential. In this research brief, we summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications.
Recent studies have highlighted the role of 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine as a modulator of neurotransmitter systems, particularly in the context of neurological and psychiatric disorders. Research published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits high affinity for serotonin and dopamine receptors, suggesting its potential as a novel therapeutic agent for conditions such as depression and schizophrenia. The study employed advanced computational modeling and in vitro assays to characterize the binding interactions of the compound with target receptors.
In addition to its neurological applications, 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine has shown promise in the field of oncology. A 2024 study published in Bioorganic & Medicinal Chemistry Letters reported that this compound exhibits selective cytotoxicity against certain cancer cell lines, including glioblastoma and breast cancer. The researchers attributed this activity to the compound's ability to inhibit key signaling pathways involved in tumor proliferation and survival. These findings open new avenues for the development of targeted cancer therapies.
The synthesis and structural optimization of 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine have also been areas of active research. A recent publication in Organic & Biomolecular Chemistry (2023) described an improved synthetic route for this compound, achieving higher yields and purity compared to previous methods. The study also explored the structure-activity relationship (SAR) of various analogs, providing valuable insights for future drug design efforts.
Despite these promising developments, challenges remain in the clinical translation of 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine. Pharmacokinetic studies have indicated that the compound exhibits limited bioavailability and rapid metabolism, which may necessitate the development of prodrug formulations or structural modifications. Ongoing research is addressing these limitations through innovative drug delivery approaches and medicinal chemistry strategies.
In conclusion, 1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine (CAS: 74852-61-2) represents a compound of significant interest in chemical biology and medicinal research. Its diverse pharmacological activities and potential therapeutic applications make it a valuable subject for continued investigation. Future studies should focus on optimizing its drug-like properties and exploring its efficacy in preclinical models of disease.
74852-61-2 (1-(4-Methyloxy-phenyl)-4-(4-nitro-phenyl)-piperazine) Related Products
- 14666-11-6(1,2-Ethanediamine, N-(4-methoxyphenyl)-N'-(4-nitrophenyl)-)
- 761440-26-0(1-(3-Methoxy-4-nitrophenyl)-4-methylpiperazine)
- 112559-81-6(4-4-(4-Nitrophenyl)-1-piperazinylphenol)
- 58315-37-0(1-(2-METHOXY-5-NITROPHENYL)PIPERAZINE)
- 1246819-65-7(1-(4-O-Methoxymethyl-4-hydroxyphenyl)-4-(4-nitrophenyl)piperazine)
- 170912-81-9(1-(2-methoxy-4-nitrophenyl)piperazine)
- 148547-50-6(Piperazine, 1-(2-methoxy-5-nitrophenyl)-4-methyl-)
- 1246819-68-0(1-(4-O-Methoxymethyl-4-hydroxyphenyl)-4-(4-nitrophenyl)piperazine-d4)
- 62988-25-4(Benzenamine, N,N-diethyl-3-(4-nitrophenoxy)-)
- 944532-73-4(1-(4-methoxy-3-nitrophenyl)piperazine)
